EyePoint appoints Jay Duker as CEO; Nancy Lurker becomes Executive Vice Chair

EyePoint, Inc.

Effective July 10, 2023, Jay Duker, M.D., promoted from COO/President to President and CEO and appointed to the Board.
Nancy Lurker transitions to Executive Vice Chair; annual base salary set at $455,000 with target bonus of 45%.
Duker receives base salary of $650,000, target bonus of 60%, and initial equity grants: 100,000 options + 50,000 RSUs.
Lurker receives options for 66,666 shares and 33,334 RSUs; she continues as Board member and Vice Chair.
Transition part of long-term succession plan; Company highlights strong balance sheet and upcoming Phase 2 trial readouts.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jay S. Duker

President and Chief Executive Officer

EYPT · EyePoint, Inc.

Effective: 2023-07-10
Filed: July 10, 2023, 7:59 PM ET

the Company appointed Dr. Duker as the Company's President and Chief Executive Officer, effective as of July 10, 2023

Appointed

Jay S. Duker

Director

EYPT · EyePoint, Inc.

Effective: 2023-07-10
Filed: July 10, 2023, 7:59 PM ET

appointed Dr. Duker to fill the vacancy for the newly created directorship

Role change

Nancy S. Lurker

Executive Vice Chair

EYPT · EyePoint, Inc.

Effective: 2023-07-10
Filed: July 10, 2023, 7:59 PM ET

Nancy S. Lurker transitioned from her role as Chief Executive Officer of EyePoint Pharmaceuticals, Inc. (the “Company”) to Executive Vice Chair of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jay S. Duker was appointed as President and Chief Executive Officer at EyePoint, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

the Company appointed Dr. Duker as the Company's President and Chief Executive Officer, effective as of July 10, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jay S. Duker was appointed as Director at EyePoint, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Dr. Duker to fill the vacancy for the newly created directorship

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy S. Lurker changed role as Executive Vice Chair at EyePoint, Inc..

Action: transitioned
Role: Executive Vice Chair

Exact text from the filing

Nancy S. Lurker transitioned from her role as Chief Executive Officer of EyePoint Pharmaceuticals, Inc. (the “Company”) to Executive Vice Chair of the Company.

View on SEC.gov

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-032324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.